Navigation Links
Bradmer announces 2008 fourth quarter and fiscal year operational and financial results
Date:3/31/2009

TSX: BMR

TORONTO, March 31 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Corporation") announced its 2008 fourth quarter and fiscal year operational and financial results.

Operational Highlights

During the year ended December 31, 2008, the Company achieved the following steps for its multi-center Phase III trial of its lead drug Neuradiab(R), a treatment for glioblastoma multiforme (GBM), the most advanced form of brain cancer:

    -   Prepared and submitted the Company's drug manufacturing data package
        and clinical dossiers to the FDA;
    -   Initiated enrollment in the Phase III GLASS-ART clinical trial;
    -   Signed contracts with and activated an initial cohort of five U.S.
        clinical trial sites;
    -   Successfully released a second GMP drug substance batch for use in
        clinical trials and filed the related update with the FDA;
    -   Submitted new data from the previous Phase II trial indicating that
        the mean time to progression free survival was 77 weeks, which
        compares favorably with other published results in newly diagnosed
        GBM (Reardon et al.; 2008 Neuro-Oncology 10:845); and
    -   Sourced and validated commercial supplies of iodine-131 outside of
        the U.S. and Europe to prevent delays in raw material supply.

Subsequent to the financial year ended December 31, 2008, the Company commenced a strategic review of its operations, as more particularly described in press releases of the Company dated February 17, 2009 and March 5, 2009. Pursuant to the strategic review, the Company has closed its Phase III GLASS ART Trial to further patient enrollment due to unforeseen delays in site initiation and recruitment, the delayed ability to complete the 60 patient "run-in phase" in a timely manner, and the inability to raise further capital at this time.

The Company
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Bradmer implements cash conservation plan
2. Bradmer provides clinical trial update and announces evaluation of strategic alternatives
3. Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
4. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
5. Bradmer announces 2008 third quarter operational and financial results
6. Bradmer to present at Rodman & Renshaw Healthcare Conference
7. Bradmer receives FDA approval to proceed with Phase III clinical trial
8. Bradmer announces 2008 first quarter operational and financial results
9. Bradmer announces new additions to management team
10. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
11. Notice of Bradmer Pharmaceuticals Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2010)... Taxes, Other Tobacco Prevention Initiatives , ... , , ... ... ... WASHINGTON , March 18 Kids in New Jersey will take center stage in the fight against tobacco on March ...
(Date:3/18/2010)... ... , , ... ... ... New Hampshire will take center stage in the fight against tobacco on March 24 as they join thousands of young people nationwide ...
(Date:3/18/2010)... President and CEO, Legacy(SM) , ... , , ... ... WASHINGTON , March ... ...
(Date:3/18/2010)... of U.S. medical students choosing internal medicine residencies ... significantly impact the shortage of primary care physicians. ... Program report, 2,722 U.S. seniors at medical schools ... 3.4 percent increase from 2,632 in 2009. The ... (2,660), 2007 (2,680), and 2006 (2,668). In comparison, ...
(Date:3/18/2010)... In its 21-year history, under the ... leaders, SRLA has trained more than 40,000 teenagers from ... area to complete the 26.2 mile Los Angeles Marathon. ... volunteer leaders will again participate in the LA Marathon. ... SRLA,s mission is to challenge at-risk secondary students to ...
Breaking Medicine News(10 mins):Health News:New Jersey Kids 'Kick Butts' on March 24 2Health News:New Jersey Kids 'Kick Butts' on March 24 3Health News:New Jersey Kids 'Kick Butts' on March 24 4Health News:New Jersey Kids 'Kick Butts' on March 24 5Health News:New Hampshire Kids 'Kick Butts' on March 24 2Health News:New Hampshire Kids 'Kick Butts' on March 24 3Health News:New Hampshire Kids 'Kick Butts' on March 24 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 2Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 3Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 5Health News:Residency match results not encouraging for adults needing primary care 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 3
... released by the government has demonstrated China’s renewed commitment to ... yuan (1.12 billion U.S. dollars) to control and prevent animal ... control animal diseases like bird flu, foot-and-mouth disease, by 2015 ... ,The central government will enable about 5.66 billion yuan ...
... cancer is the fourth leading cause of cancer death in ... from the disease this year.// ,Pancreatic cancer is ... about what causes it. One established risk factor in pancreatic ... obesity, diabetes type 2 and insulin resistance. In a new ...
... research finding reveals that there may exist a link between ... Dr. Rebecca Fitzgerald of Medical Research Council Cell Unit and ... due to the malformation of the oesophageal lining. This condition ... lining of the oesophageal wall is slowly changed to glandular ...
... A new study reported in Tuesday’s issue of Canadian Journal ... have accounted to over 3% (40,000) of 1.2 million emergency ... ,The study Researchers at the Toronto-based Institute for ... wounds in Ontario's 180 hospitals between April 1, 2002 and ...
... tumor cells that indicates which cells are capable of fueling ... cancer stem cells in head and neck tumors.// ,Cancer ... replicate to drive tumor growth. Researchers believe current cancer treatments ... cells. By identifying the stem cells, researchers can then develop ...
... on contract went on strike from Tuesday demanding regularisation of ... years ago on contract. Their contract is due to end ... regularised. ,Representatives of these doctors held a meeting ... failed to reach any agreement. ,The doctors decided ...
Other Medicine News:Health News:Link Found Between Periodontal Disease and Pancreatic Cancer 2Health News:Stem Cell Marker Identified in Head and Neck Cancer 2
(Date:3/18/2010)... March 18 Poniard Pharmaceuticals, Inc. ... innovative oncology therapies, today announced that the U.S. Patent ... the composition of matter patent for picoplatin as RE41209, ... 2010 . The reissue was applied for May ... , the USPTO released the "Issue Notification" for the ...
(Date:3/18/2010)... , March 18 ... Chief Executive Officer, Pfizer, was elected board ... of America (PhRMA) today at the trade ... Chief Executive Officer Christopher Viehbacher ... Directors, and John C. Lechleiter , ...
(Date:3/18/2010)... results in too much ammonia in the blood. , ... , , ... ... (Logo: ... ...
Breaking Medicine Technology:U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 2U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 3U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 4U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 2FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 3FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 4FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 5Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 1Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 2Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 3Exposure to lead tobacco smoke raises risk of ADHD 10856 1Exposure to lead tobacco smoke raises risk of ADHD 10856 2Measuring and modeling blood flow in malaria 61892 1Measuring and modeling blood flow in malaria 61892 2
... and proof of concept in topical models of,infection ... - Arpida Ltd.,(SWX: ARPN) today announced positive results ... large panel of,clinical isolates, including those resistant to ... were found,to be highly effective in eradicating methicillin ...
... UK scientists in Glasgow,have devised a new method ... the Journal of Clinical Investigation* today,(Thursday). , A ... Cancer,Research gave mice a chemical that caused cancer ... the tumours they were,carrying. The chemical kick started ...
Other Medicine Technology:Arpida adds novel antibiotic AR-2474 to its preclinical pipeline 2Arpida adds novel antibiotic AR-2474 to its preclinical pipeline 3Scottish Scientists Test ‘Secret Weapon’ Against,Tumours 2Scottish Scientists Test ‘Secret Weapon’ Against,Tumours 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: